These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33364940)

  • 1. The Use of Ozenoxacin in Pediatric Patients: Clinical Evidence, Efficacy and Safety.
    Davino G; D'Alvano T; Esposito S
    Front Pharmacol; 2020; 11():559708. PubMed ID: 33364940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ozenoxacin: A Novel Topical Quinolone for Impetigo.
    Wren C; Bell E; Eiland LS
    Ann Pharmacother; 2018 Dec; 52(12):1233-1237. PubMed ID: 29962213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical Ozenoxacin Cream 1% for Impetigo: A Review.
    Schachner L; Andriessen A; Bhatia N; Grada A; Patele D
    J Drugs Dermatol; 2019 Jul; 18(7):655-661. PubMed ID: 31334625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impetigo: diagnosis and treatment.
    Hartman-Adams H; Banvard C; Juckett G
    Am Fam Physician; 2014 Aug; 90(4):229-35. PubMed ID: 25250996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ozenoxacin: a review of preclinical and clinical efficacy.
    Vila J; Hebert AA; Torrelo A; López Y; Tato M; García-Castillo M; Cantón R
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):159-168. PubMed ID: 30686133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of ozenoxacin in animal models of dermal infection with Staphylococcus aureus.
    Tarragó C; Esquirol LP; Arañó A; Lachamp L; D'Aniello F; Zsolt I
    Future Microbiol; 2018 May; 13():21-30. PubMed ID: 29745240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
    Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
    J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis.
    López Y; Tato M; Gargallo-Viola D; Cantón R; Vila J; Zsolt I
    PLoS One; 2019; 14(10):e0223326. PubMed ID: 31596898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impetigo update: new challenges in the era of methicillin resistance.
    Geria AN; Schwartz RA
    Cutis; 2010 Feb; 85(2):65-70. PubMed ID: 20349679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ozenoxacin: A Novel Drug Discovery for the Treatment of Impetigo.
    Sahu JK; Mishra AK
    Curr Drug Discov Technol; 2019; 16(3):259-264. PubMed ID: 29732990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic applications of ozenoxacin in superficial skin infections.
    García Ron G; Villa Arranz M
    Dermatol Reports; 2022 Jun; 14(2):9289. PubMed ID: 35795839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.
    Torrelo A; Grimalt R; Masramon X; Albareda López N; Zsolt I
    Dermatology; 2020; 236(3):199-207. PubMed ID: 31958794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.
    Rosen T; Albareda N; Rosenberg N; Alonso FG; Roth S; Zsolt I; Hebert AA
    JAMA Dermatol; 2018 Jul; 154(7):806-813. PubMed ID: 29898217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility of Staphylococcus aureus isolated from children with impetigo in China from 2003 to 2007 shows community-associated methicillin-resistant Staphylococcus aureus to be uncommon and heterogeneous.
    Liu Y; Kong F; Zhang X; Brown M; Ma L; Yang Y
    Br J Dermatol; 2009 Dec; 161(6):1347-50. PubMed ID: 19754868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impetigo.
    Johnson MK
    Adv Emerg Nurs J; 2020; 42(4):262-269. PubMed ID: 33105179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.
    Gropper S; Albareda N; Chelius K; Kruger D; Mitha I; Vahed Y; Gani M; García-Alonso F;
    Future Microbiol; 2014; 9(9):1013-23. PubMed ID: 25340832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo.
    Gropper S; Cepero AL; Santos B; Kruger D
    Future Microbiol; 2014; 9(8 Suppl):S33-40. PubMed ID: 25209523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impetigo: an overview.
    Darmstadt GL; Lane AT
    Pediatr Dermatol; 1994 Dec; 11(4):293-303. PubMed ID: 7899177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ozenoxacin 1% cream (Xepi) for impetigo.
    Med Lett Drugs Ther; 2019 Apr; 61(1570):63-64. PubMed ID: 31169810
    [No Abstract]   [Full Text] [Related]  

  • 20. Bacterial diseases of the skin.
    Edlich RF; Winters KL; Britt LD; Long WB
    J Long Term Eff Med Implants; 2005; 15(5):499-510. PubMed ID: 16218899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.